These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 27395567

  • 1. Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.
    van den Dobbelsteen GPJM, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT.
    Vaccine; 2016 Jul 29; 34(35):4152-4160. PubMed ID: 27395567
    [Abstract] [Full Text] [Related]

  • 2. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.
    Clin Vaccine Immunol; 2016 Dec 29; 23(12):908-917. PubMed ID: 27581434
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical Studies of Escherichia coli O157:H7 Conjugate Vaccines in Adults and Young Children.
    Szu SC, Ahmed A.
    Microbiol Spectr; 2014 Dec 29; 2(6):. PubMed ID: 26104443
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers.
    Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ.
    J Infect Dis; 1994 Oct 29; 170(4):834-40. PubMed ID: 7523536
    [Abstract] [Full Text] [Related]

  • 6. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults.
    Konadu EY, Parke JC, Tran HT, Bryla DA, Robbins JB, Szu SC.
    J Infect Dis; 1998 Feb 29; 177(2):383-7. PubMed ID: 9466525
    [Abstract] [Full Text] [Related]

  • 7. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.
    J Immunol Methods; 2017 Nov 29; 450():27-33. PubMed ID: 28735760
    [Abstract] [Full Text] [Related]

  • 8. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.
    Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, Williamson D, Atkins TP, Prior JL, Wren BW.
    Open Biol; 2013 May 22; 3(5):130002. PubMed ID: 23697804
    [Abstract] [Full Text] [Related]

  • 9. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
    Ho MM, Bolgiano B, Martino A, Kairo SK, Corbel MJ.
    Hum Vaccin; 2006 May 22; 2(3):89-98. PubMed ID: 17012902
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.
    Hatz CF, Bally B, Rohrer S, Steffen R, Kramme S, Siegrist CA, Wacker M, Alaimo C, Fonck VG.
    Vaccine; 2015 Aug 26; 33(36):4594-601. PubMed ID: 26162850
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease.
    Chorro L, Ndreu D, Patel A, Kodali S, Li Z, Keeney D, Dutta K, Sasmal A, Illenberger A, Torres CL, Pan R, Silmon de Monerri NC, Chu L, Simon R, Anderson AS, Donald RGK.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0421323. PubMed ID: 38700324
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A.
    Lancet Infect Dis; 2021 Apr 04; 21(4):546-558. PubMed ID: 33186516
    [Abstract] [Full Text] [Related]

  • 14. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.
    Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR.
    Vaccine; 2007 May 10; 25(19):3859-70. PubMed ID: 17306426
    [Abstract] [Full Text] [Related]

  • 15. A biologically conjugated polysaccharide vaccine delivered by attenuated Salmonella Typhimurium provides protection against challenge of avian pathogenic Escherichia coli O1 infection.
    Han Y, Liu Q, Yi J, Liang K, Wei Y, Kong Q.
    Pathog Dis; 2017 Nov 30; 75(8):. PubMed ID: 28911037
    [Abstract] [Full Text] [Related]

  • 16. High efficiency biosynthesis of O-polysaccharide-based vaccines against extraintestinal pathogenic Escherichia coli.
    Jiang X, Bai J, Yuan J, Zhang H, Lu G, Wang Y, Jiang L, Liu B, Wang L, Huang D, Feng L.
    Carbohydr Polym; 2021 Mar 01; 255():117475. PubMed ID: 33436239
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children.
    Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC.
    J Infect Dis; 2006 Feb 15; 193(4):515-21. PubMed ID: 16425130
    [Abstract] [Full Text] [Related]

  • 18. Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.
    Ravenscroft N, Braun M, Schneider J, Dreyer AM, Wetter M, Haeuptle MA, Kemmler S, Steffen M, Sirena D, Herwig S, Carranza P, Jones C, Pollard AJ, Wacker M, Kowarik M.
    Glycobiology; 2019 Aug 20; 29(9):669-680. PubMed ID: 31206156
    [Abstract] [Full Text] [Related]

  • 19. Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic Escherichia coli antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota.
    Naili I, Vinot J, Baudner BC, Bernalier-Donadille A, Pizza M, Desvaux M, Jubelin G, D'Oro U, Buonsanti C.
    Vaccine; 2019 Jan 07; 37(2):314-324. PubMed ID: 30503655
    [Abstract] [Full Text] [Related]

  • 20. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli.
    Huttner A, Gambillara V.
    Clin Microbiol Infect; 2018 Oct 07; 24(10):1046-1050. PubMed ID: 29803843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.